Score system stratifying AML patients.

DFS (A) and OS (B) of all patients and DFS (C) and OS (D) of patients with normal cytogenetics. The factors of poor prognosis include a WHO performance status greater than 2, a positive Pgp activity, expression of only 1-4 myeloid markers, and older age (at least 60 years).